Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma

A. E. Frankel; S. L. Zuckero; A. A. Mankin; M. Grable; K. Mitchell; Y. J. Lee; D. M. Neville; J. H. Woo

doi:10.2174/138945009787354539

Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma

A. E. Frankel, S. L. Zuckero, A. A. Mankin, M. Grable, K. Mitchell, Y. J. Lee, D. M. Neville, J. H. Woo

Research output: Contribution to journal › Review article › peer-review

51 Scopus citations

Abstract

The recombinant CD3 immunotoxin, A-dmDT₃₉₀-bisFv(UCHT1), composed of the catalytic and translocation domains of diphtheria toxin fused to two single chain Fv fragments of an anti-CD3ε monoclonal antibody was administered to five patients with cutaneous T cell lymphoma (CTCL) by eight 15 min intravenous infusions over four days. Side effects were fever, chills, nausea, hypoalbuminemia, transaminasemia and reactivation of EBV and CMV. Half-life of drug was 40 min. Anti-immunotoxin antibodies developed in all patients after two weeks. Two patients had partial remissions lasting 1 and 6+ months. The agent is undergoing further dose escalation and shows promising results in this disease.

Original language	English (US)
Pages (from-to)	104-109
Number of pages	6
Journal	Current Drug Targets
Volume	10
Issue number	2
DOIs	https://doi.org/10.2174/138945009787354539
State	Published - 2009

Keywords

Cutaneous T cell lymphoma
Diphtheria toxin
Immunotoxin

ASJC Scopus subject areas

Molecular Medicine
Pharmacology
Drug Discovery
Clinical Biochemistry

Access to Document

10.2174/138945009787354539

Cite this

@article{c0e3382aed5b42d3a4dd06d5a193dae1,

title = "Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma",

abstract = "The recombinant CD3 immunotoxin, A-dmDT390-bisFv(UCHT1), composed of the catalytic and translocation domains of diphtheria toxin fused to two single chain Fv fragments of an anti-CD3ε monoclonal antibody was administered to five patients with cutaneous T cell lymphoma (CTCL) by eight 15 min intravenous infusions over four days. Side effects were fever, chills, nausea, hypoalbuminemia, transaminasemia and reactivation of EBV and CMV. Half-life of drug was 40 min. Anti-immunotoxin antibodies developed in all patients after two weeks. Two patients had partial remissions lasting 1 and 6+ months. The agent is undergoing further dose escalation and shows promising results in this disease.",

keywords = "Cutaneous T cell lymphoma, Diphtheria toxin, Immunotoxin",

author = "Frankel, {A. E.} and Zuckero, {S. L.} and Mankin, {A. A.} and M. Grable and K. Mitchell and Lee, {Y. J.} and Neville, {D. M.} and Woo, {J. H.}",

year = "2009",

doi = "10.2174/138945009787354539",

language = "English (US)",

volume = "10",

pages = "104--109",

journal = "Current Drug Targets",

issn = "1389-4501",

publisher = "Bentham Science Publishers B.V.",

number = "2",

}

TY - JOUR

T1 - Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma

AU - Frankel, A. E.

AU - Zuckero, S. L.

AU - Mankin, A. A.

AU - Grable, M.

AU - Mitchell, K.

AU - Lee, Y. J.

AU - Neville, D. M.

AU - Woo, J. H.

PY - 2009

Y1 - 2009

N2 - The recombinant CD3 immunotoxin, A-dmDT390-bisFv(UCHT1), composed of the catalytic and translocation domains of diphtheria toxin fused to two single chain Fv fragments of an anti-CD3ε monoclonal antibody was administered to five patients with cutaneous T cell lymphoma (CTCL) by eight 15 min intravenous infusions over four days. Side effects were fever, chills, nausea, hypoalbuminemia, transaminasemia and reactivation of EBV and CMV. Half-life of drug was 40 min. Anti-immunotoxin antibodies developed in all patients after two weeks. Two patients had partial remissions lasting 1 and 6+ months. The agent is undergoing further dose escalation and shows promising results in this disease.

AB - The recombinant CD3 immunotoxin, A-dmDT390-bisFv(UCHT1), composed of the catalytic and translocation domains of diphtheria toxin fused to two single chain Fv fragments of an anti-CD3ε monoclonal antibody was administered to five patients with cutaneous T cell lymphoma (CTCL) by eight 15 min intravenous infusions over four days. Side effects were fever, chills, nausea, hypoalbuminemia, transaminasemia and reactivation of EBV and CMV. Half-life of drug was 40 min. Anti-immunotoxin antibodies developed in all patients after two weeks. Two patients had partial remissions lasting 1 and 6+ months. The agent is undergoing further dose escalation and shows promising results in this disease.

KW - Cutaneous T cell lymphoma

KW - Diphtheria toxin

KW - Immunotoxin

UR - http://www.scopus.com/inward/record.url?scp=64249158870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64249158870&partnerID=8YFLogxK

U2 - 10.2174/138945009787354539

DO - 10.2174/138945009787354539

M3 - Review article

C2 - 19199905

AN - SCOPUS:64249158870

SN - 1389-4501

VL - 10

SP - 104

EP - 109

JO - Current Drug Targets

JF - Current Drug Targets

IS - 2

ER -

Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this